B-cell Acute Lymphoblastic Leukemia research hub
16 indexed studies · 7 currently recruiting
- recruitingPHASE1, PHASE2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
This study is testing a new drug, Zilovertamab Vedotin, for children and young adults aged 6 months to 25 years with certain blood cancers (like some types of leukaemia and lymphoma) and solid tumours (like neuroblastoma and Ewing sarcoma) that have come back or not responded to previous treatments.
United States · Australia · Belgium - recruitingPHASE2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
This study is testing a new medicine called Naxitamab for children and young people recently diagnosed with a serious type of cancer called high-risk neuroblastoma. It's given alongside their usual chemotherapy to see if it helps treatment work better and improves their chances of recovery.
United States · Canada - active not recruiting
DOTATOC PET/CT for Imaging NET Patients
This study looks at a new type of scan called 68Ga-DOTATOC PET/CT for checking on neuroendocrine tumours (NETs) and similar growths. It compares it to a standard scan to see if it’s better at finding these conditions safely.
Canada - active not recruitingNA
Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)
This study looks at DNA and immune system features in childhood, teenage, and young adult cancers like neuroblastoma and leukaemia. We aim to better understand these high-risk cancers from diagnosis through treatment to find new ways to help. Participants give blood, bone marrow, or spinal fluid samples.
France - active not recruitingPHASE2
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
This study looks at a new drug, palbociclib, combined with standard chemotherapy for children, teenagers, and young adults with certain cancers that have come back or are hard to treat. It aims to find a safe dose and see how well it works.
United States · Brazil · Canada - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This study is testing a cancer drug called capmatinib to see if it can help adults with different types of cancer that share a specific genetic change (MET mutation). It's already approved for some lung cancers, and now researchers want to know if it works for other cancers too.
United Kingdom - active not recruitingPHASE1
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
This study is looking at a new medicine called LY3295668 erbumine for children and young people aged 2 to 21 with a type of cancer called neuroblastoma. We want to find out if this medicine is safe when neuroblastoma has come back or not responded to other treatments.
United States · Australia · Belgium - recruitingPHASE2
68Ga-DOTATATE Neuroblastoma Imaging Pilot
This study looks at a new way to scan children and young adults with neuroblastoma, a type of cancer. It compares a new scanning method (68Ga-DOTATATE PET/CT) with a standard one (123I-MIBG) to see if it's safe and helps doctors get clearer pictures of the cancer.
Canada - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This study is testing a drug called alectinib for different types of cancer that have a special gene change called ALK. It's already used for some lung cancers, and now doctors want to see if it can help other cancers with the same change.
United Kingdom - active not recruitingPHASE2
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
This study looks at combining existing treatments for high-risk neuroblastoma to see if it works better. It's for children and young people who have already had intensive therapy, to help prevent the cancer from coming back.
United States · Australia · Canada - ongoing, recruitingTherapeutic exploratory (Phase II)
BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma
This study looks at new ways to treat children with neuroblastoma that has come back or not responded to previous treatments. It combines standard chemotherapy drugs with a new medicine called bevacizumab to see if this helps shrink the cancer or stop it from growing.
Belgium · Spain · Netherlands - active not recruitingPHASE1
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
This study is looking at new ways to treat neuroblastoma in children, a type of cancer. It combines standard treatment with new medicines (Nivolumab and Dinutuximab Beta) to see if they are safe and helpful. The goal is to find better treatments for children whose cancer has come back or is hard to treat.
United States · United Kingdom - active not recruitingPHASE2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
This study is for children and adults with a type of high-risk neuroblastoma that hasn't fully responded to previous treatments. It investigates a new approach using two medicines, Naxitamab and GM-CSF, to see if they can help manage the condition.
United States · Canada · Denmark - recruiting
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
This study is gathering information on children and teenagers with a type of cancer called neuroblastoma. It's looking at how safe and effective a medicine called dinutuximab beta is when used in real-world situations, observing patients over time to understand its long-term effects.
Austria · France · Germany - recruitingPHASE3
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
This study looks at new ways to treat a serious childhood cancer called neuroblastoma. It tests different treatment combinations, including chemotherapy and immunotherapy, to find the best approach for children with high-risk forms of the disease. The aim is to improve their chances of getting better.
Australia · Austria · Belgium - active not recruitingPHASE1
Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
This study, MAGNETO, is for children aged 1-16 with neuroblastoma that has come back or not responded to previous treatments. It tests a new type of treatment called GD2 CAR T cells to see if it's safe and can be made successfully. It's an early-stage study.
United Kingdom